# Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

> **NCT00224393** · PHASE2 · COMPLETED · sponsor: **The Cleveland Clinic** · enrollment: 60 (—)

## Conditions studied

- Primary Systemic Amyloidosis

## Interventions

- **DRUG:** Enbrel

## Key facts

- **NCT ID:** NCT00224393
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2005-08-31
- **Target enrollment:** 60 (—)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00224393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00224393, "Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00224393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*